The United States Department of Agriculture (USDA) has approved Carravet® Acemannan Immunostimulant for use in the treatment of fibrosarcomas in dogs and cats. Fibrosarcoma is amalignant tumor of connective tissue such as bone, muscle and cartilage. Surgical removal of fibrosarcoma is difficult because of the way it grows. It sends out finger-like projections that attach to surrounding tissue. Because the tumor is so spread out, it can be difficult to completely remove. Subsequently, the tumor recurs and leads to additional surgeries, possible amputation of affected limbs and/or death. These tumors do not respond well to chemotherapy.

The incidence of fibrosarcomas is on the rise, especially in cats. These tumors have been associated with reactions at vaccination sites.

Carravet® Acemannan Immunostimulant manufactured by Carrington Laboratories, Inc., is a natural product refined from the aloe plant. It works by stimulating the immune system to encapsulate, or ‘wrap up’ the tumor. Following the treatment, the tumor may have clearly defined edges and it becomes easier to successfully remove the entire tumor.

Acemannan is most effective when combined with surgery and radiation. The product is injected into the animal and into the tumor itself.